195 related articles for article (PubMed ID: 3469013)
1. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
Danks MK; Yalowich JC; Beck WT
Cancer Res; 1987 Mar; 47(5):1297-301. PubMed ID: 3469013
[TBL] [Abstract][Full Text] [Related]
2. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Wolverton JS; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
[TBL] [Abstract][Full Text] [Related]
3. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
8. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Chen M; Beck WT
Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
[TBL] [Abstract][Full Text] [Related]
10. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
11. Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.
Lee T; Roberts D
Cancer Res; 1984 Jul; 44(7):2986-90. PubMed ID: 6722822
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to vincristine.
Conter V; Beck WT
Cancer Treat Rep; 1984 Jun; 68(6):831-9. PubMed ID: 6539648
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.
White JC; Hines LH; Rathmell JP
Cancer Res; 1985 Jul; 45(7):3070-5. PubMed ID: 4005845
[TBL] [Abstract][Full Text] [Related]
14. Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts.
Dow LW; Sinkule JA; Look AT; Horvath A; Evans WE
Cancer Res; 1983 Dec; 43(12 Pt 1):5699-706. PubMed ID: 6580063
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance patterns and antigen expression in Vinca alkaloid- and other multiple drug-resistant human leukemic cell lines.
Beck WT; Danks MK; Cirtain MC; van Heiningen JN
Prog Clin Biol Res; 1986; 223():3-10. PubMed ID: 3468517
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
Harker WG; Slade DL; Dalton WS; Meltzer PS; Trent JM
Cancer Res; 1989 Aug; 49(16):4542-9. PubMed ID: 2568172
[TBL] [Abstract][Full Text] [Related]
17. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.
Danks MK; Schmidt CA; Deneka DA; Beck WT
Cancer Commun; 1989; 1(2):101-9. PubMed ID: 2561733
[TBL] [Abstract][Full Text] [Related]
18. Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.
Gupta RS
Cancer Res; 1983 Apr; 43(4):1568-74. PubMed ID: 6831403
[No Abstract] [Full Text] [Related]
19. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
20. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
